Potential of resveratrol analogues as antagonists of osteoclasts and promoters of osteoblasts

Calcified Tissue International

Volumn 87, Issue 5, 2010, Pages 437-449

  Kupisiewicz, Katarzyna ^a   Boissy, Patrice ^a   Abdallah, Basem M ^b   Hansen, Frederik Dagnaes ^c   Erben, Reinhold G ^d   Savouret, Jean Francois ^e   Søe, Kent ^a   Andersen, Thomas L ^a   Plesner, Torben ^a   Delaisse, Jean Marie ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Multiple myeloma; Osteoblast; Osteoclast; Resveratrol; Resveratrol analogue

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RESVERATROL; TRANSCRIPTION FACTOR NFAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE REMODELING; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MYELOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTICARCINOGENIC AGENTS; BONE DENSITY CONSERVATION AGENTS; CELL LINE, TUMOR; FEMALE; GROWTH INHIBITORS; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; RATS; STILBENES; TREATMENT OUTCOME;

EID: 78650173542     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-010-9399-3     Document Type: Article

References (51)

1. M Jang L Cai GO Udeani KV Slowing CF Thomas CW Beecher HH Fong NR Farnsworth AD Kinghorn RG Mehta RC Moon JM Pezzuto 1997 Cancer chemopreventive activity of resveratrol, a natural product derived from grapes Science 275 218 220 1:CAS:528:DyaK2sXks1Sjtw%3D%3D 10.1126/science.275.5297.218 8985016
2. Z Dong 2003 Molecular mechanism of the chemopreventive effect of resveratrol Mutat Res 523-524 145 150 12628512
3. S Pervaiz 2003 Resveratrol: from grapevines to mammalian biology FASEB J 17 1975 1985 1:CAS:528:DC%2BD3sXovFOmtr0%3D 10.1096/fj.03-0168rev 14597667 (Pubitemid 37392442)
4. S Banerjee C Bueso-Ramos BB Aggarwal 2002 Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9 Cancer Res 62 4945 4954 1:CAS:528:DC%2BD38Xmslylu7s%3D 12208745
5. L Yu ZJ Sun SL Wu CE Pan 2003 Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer World J Gastroenterol 9 2341 2343 1:CAS:528:DC%2BD3sXpsVOjtbs%3D 14562407
6. Y Schneider B Duranton F Gosse R Schleiffer N Seiler F Raul 2001 Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis Nutr Cancer 39 102 107 1:CAS:528:DC%2BD3MXnsVCnurk%3D 10.1207/S15327914nc391-14 11588890
7. L Tessitore A Davit I Sarotto G Caderni 2000 Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression Carcinogenesis 21 1619 1622 1:CAS:528:DC%2BD3cXlvVeqtLs%3D 10.1093/carcin/21.8.1619 10910967
8. Y Kimura H Okuda 2001 Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice J Nutr 131 1844 1849 1:CAS:528:DC%2BD3MXkt12ksbg%3D 11385077
9. Y Chen SH Tseng HS Lai WJ Chen 2004 Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice Surgery 136 57 66 10.1016/j.surg.2004.01.017 15232540 (Pubitemid 38834220)
10. P Boissy TL Andersen BM Abdallah M Kassem T Plesner JM Delaisse 2005 Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation Cancer Res 65 9943 9952 1:CAS:528: DC%2BD2MXhtFKktLjJ 10.1158/0008-5472.CAN-05-0651 16267019 (Pubitemid 41541475)
11. K Mizutani K Ikeda Y Kawai Y Yamori 1998 Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells Biochem Biophys Res Commun 253 859 863 1:CAS:528:DyaK1MXjs1Gnsw%3D%3D 10.1006/bbrc.1998.9870 9918820 (Pubitemid 29039235)
12. SU Singh RF Casper PC Fritz B Sukhu B Ganss B Girard Jr JF Savouret HC Tenenbaum 2000 Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol J Endocrinol 167 183 195 1:CAS:528:DC%2BD3MXptVehtg%3D%3D 10.1677/joe.0.1670183 11018766
13. E Ulsperger G Hamilton M Raderer G Baumgartner M Hejna O Hoffmann R Mallinger 1999 Resveratrol pretreatment desensitizes AHTO-7 human osteoblasts to growth stimulation in response to carcinoma cell supernatants Int J Oncol 15 955 959 1:CAS:528:DyaK1MXnsFGisLg%3D 10536179
14. D Clerc JP Fermand X Mariette 2003 Treatment of multiple myeloma Joint Bone Spine 70 175 186 10.1016/S1297-319X(03)00018-6 12814760 (Pubitemid 36753469)
15. C Sun Y Hu X Liu T Wu Y Wang W He W Wei 2006 Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis Cancer Genet Cytogenet 165 9 19 1:CAS:528:DC%2BD28XhsFKrtro%3D 10.1016/j.cancergencyto.2005.06.016 16490592 (Pubitemid 43254647)
16. CY Sun Y Hu T Guo HF Wang XP Zhang WJ He H Tan 2006 Resveratrol as a novel agent for treatment of multiple myeloma with matrix metalloproteinase inhibitory activity Acta Pharmacol Sin 27 1447 1452 1:CAS:528:DC%2BD28Xht1WkurrF 10.1111/j.1745-7254.2006.00343.x 17049120 (Pubitemid 44630312)
17. KC Anderson JD Shaughnessy Jr B Barlogie JL Harousseau GD Roodman 2002 Multiple myeloma Hematology Am Soc Hematol Educ Program 1 214 240
18. DM Goldberg J Yan GJ Soleas 2003 Absorption of three wine-related polyphenols in three different matrices by healthy subjects Clin Biochem 36 79 87 1:CAS:528:DC%2BD3sXitVertLk%3D 10.1016/S0009-9120(02)00397-1 12554065 (Pubitemid 36126394)
19. JF Marier P Vachon A Gritsas J Zhang JP Moreau MP Ducharme 2002 Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model J Pharmacol Exp Ther 302 369 373 1:CAS:528:DC%2BD38Xlt1SnsLg%3D 10.1124/jpet.102.033340 12065739 (Pubitemid 34680460)
20. JA Crowell PJ Korytko RL Morrissey TD Booth BS Levine 2004 Resveratrol-associated renal toxicity Toxicol Sci 82 614 619 1:CAS:528:DC%2BD2cXhtVSru7bO 10.1093/toxsci/kfh263 15329443 (Pubitemid 39600090)
21. JL Bowers VV Tyulmenkov SC Jernigan CM Klinge 2000 Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta Endocrinology 141 3657 3667 1:CAS:528:DC%2BD3cXmvVGmsL4%3D 10.1210/en.141.10.3657 11014220
22. H Stopper E Schmitt K Kobras 2005 Genotoxicity of phytoestrogens Mutat Res 574 139 155 1:CAS:528:DC%2BD2MXks1eitL4%3D 15914213
23. K Ashikawa S Majumdar S Banerjee AC Bharti S Shishodia BB Aggarwal 2002 Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation J Immunol 169 6490 6497 1:CAS:528:DC%2BD38Xpt1KlsLw%3D 12444159
24. M Murias W Jager N Handler T Erker Z Horvath T Szekeres H Nohl L Gille 2005 Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship Biochem Pharmacol 69 903 912 1:CAS:528:DC%2BD2MXhvVCiu70%3D 10.1016/j.bcp.2004.12.001 15748702 (Pubitemid 40312708)
25. Mundy GR, Edwards JR, Zainabadi K, Elefteriou F, Alt F, Guarente L (2008) The aging associated gene SIRT-1 controls bone mass in vivo through osteoblast and osteoclast regulation. Bone S49
26. P de Medina R Casper JF Savouret M Poirot 2005 Synthesis and biological properties of new stilbene derivatives of resveratrol as new selective aryl hydrocarbon modulators J Med Chem 48 287 291 10.1021/jm0498194 15634023 (Pubitemid 40105267)
27. AK Shiau D Barstad PM Loria L Cheng PJ Kushner DA Agard GL Greene 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen Cell 95 927 937 1:CAS:528: DyaK1MXjslyltQ%3D%3D 10.1016/S0092-8674(00)81717-1 9875847 (Pubitemid 29019045)
28. A Zallone 2006 Direct and indirect estrogen actions on osteoblasts and osteoclasts Ann N Y Acad Sci 1068 173 179 1:CAS:528:DC%2BD28XntFentb0%3D 10.1196/annals.1346.019 16831916 (Pubitemid 43824147)
29. SD Dertinger DA Nazarenko AE Silverstone TA Gasiewicz 2001 Aryl hydrocarbon receptor signaling plays a significant role in mediating benzo[a]pyrene- and cigarette smoke condensate-induced cytogenetic damage in vivo Carcinogenesis 22 171 177 1:CAS:528:DC%2BD3MXptVertQ%3D%3D 10.1093/carcin/22.1.171 11159756
30. PK Mandal 2005 Dioxin: a review of its environmental effects and its aryl hydrocarbon receptor biology J Comp Physiol B 175 221 230 1:CAS:528: DC%2BD2MXkt1Sgur0%3D 10.1007/s00360-005-0483-3 15900503 (Pubitemid 40764087)
31. JL Marlowe A Puga 2005 Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis J Cell Biochem 96 1174 1184 1:CAS:528: DC%2BD2MXht1KgtbfM 10.1002/jcb.20656 16211578 (Pubitemid 41681860)
32. KW Bock 1994 Aryl hydrocarbon or dioxin receptor: biologic and toxic responses Rev Physiol Biochem Pharmacol 125 1 42 1:CAS:528:DyaK2MXivFWqsL4%3D 10.1007/BFb0030908 7984872
33. EP Ryan JD Holz M Mulcahey TJ Sheu TA Gasiewicz JE Puzas 2007 Environmental toxicants may modulate osteoblast differentiation by a mechanism involving the aryl hydrocarbon receptor J Bone Miner Res 22 1571 1580 1:CAS:528:DC%2BD2sXhtFyhu7bM 10.1359/jbmr.070615 17576166 (Pubitemid 351229327)
34. BM Abdallah M Haack-Sorensen JS Burns B Elsnab F Jakob P Hokland M Kassem 2005 Maintenance of differentiation potential of human bone marrow mesenchymal stem cells immortalized by human telomerase reverse transcriptase gene despite extensive proliferation Biochem Biophys Res Commun 326 527 538 1:CAS:528:DC%2BD2cXhtVKltrfO 10.1016/j.bbrc.2004.11.059 15596132 (Pubitemid 39642757)
35. JL Simonsen C Rosada N Serakinci J Justesen K Stenderup SI Rattan TG Jensen M Kassem 2002 Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells Nat Biotechnol 20 592 596 1:CAS:528:DC%2BD38XktFOiu7s%3D 10.1038/nbt0602-592 12042863 (Pubitemid 34595153)
36. BM Abdallah CH Jensen G Gutierrez RG Leslie TG Jensen M Kassem 2004 Regulation of human skeletal stem cells differentiation by Dlk1/Pref-1 J Bone Miner Res 19 841 852 1:CAS:528:DC%2BD2cXktFGks7g%3D 10.1359/jbmr.040118 15068508 (Pubitemid 41094396)
37. LJ Robinson BB Yaroslavskiy RD Griswold EV Zadorozny L Guo IL Tourkova HC Blair 2009 Estrogen inhibits RANKL-stimulated osteoclastic differentiation of human monocytes through estrogen and RANKL-regulated interaction of estrogen receptor-alpha with BCAR1 and Traf6 Exp Cell Res 315 1287 1301 1:CAS:528:DC%2BD1MXktF2ktrg%3D 10.1016/j.yexcr.2009.01.014 19331827
38. M Shinohara H Takayanagi 2007 Novel osteoclast signaling mechanisms Curr Osteoporos Rep 5 67 72 10.1007/s11914-007-0005-1 17521508
39. DU Ferreiro EA Komives 2010 Molecular mechanisms of system control of NF-kappaB signaling by IkappaBalpha Biochemistry 49 1560 1567 1:CAS:528:DC%2BC3cXhsFantrs%3D 10.1021/bi901948j 20055496
40. A Seifert S Rau G Kullertz B Fischer AN Santos 2009 TCDD induces cell migration via NFATc1/ATX-signaling in MCF-7 cells Toxicol Lett 184 26 32 1:CAS:528:DC%2BD1cXhsFagtrnI 10.1016/j.toxlet.2008.10.026 19028555
41. I Voronov K Li HC Tenenbaum MF Manolson 2008 Benzo[a]pyrene inhibits osteoclastogenesis by affecting RANKL-induced activation of NF-kappaB Biochem Pharmacol 75 2034 2044 1:CAS:528:DC%2BD1cXlsFOmsbw%3D 10.1016/j.bcp.2008.02.025 18396263
42. I Voronov JN Heersche RF Casper HC Tenenbaum MF Manolson 2005 Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration Biochem Pharmacol 70 300 307 1:CAS:528:DC%2BD2MXlt1SktLw%3D 10.1016/j.bcp.2005.04.028 15919055 (Pubitemid 40814411)
43. E Seeman PD Delmas 2006 Bone quality-the material and structural basis of bone strength and fragility N Engl J Med 354 2250 2261 1:CAS:528: DC%2BD28XkvVShsbw%3D 10.1056/NEJMra053077 16723616
44. CM Backesjo Y Li U Lindgren LA Haldosen 2006 Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells J Bone Miner Res 21 993 1002 10.1359/jbmr.060415 16813520 (Pubitemid 43962828)
45. IE El Hajj Dib G Melanie S Valery M Romuald B Michel S Kamel 2008 Multiple myeloma cells directly stimulate bone resorption in vitro by down-regulating mature osteoclast apoptosis Leuk Res 32 1279 1287 1:CAS:528:DC%2BD1cXlvVSqsL0%3D 10.1016/j.leukres.2007.12.018 18282599
46. M Hecht I von Metzler K Sack M Kaiser O Sezer 2008 Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA) Exp Cell Res 314 1082 1093 1:CAS:528:DC%2BD1cXisVWjtLY%3D 10.1016/j.yexcr.2007. 10.021 18053985 (Pubitemid 351273201)
47. S Yaccoby RN Pearse CL Johnson B Barlogie Y Choi J Epstein 2002 Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity Br J Haematol 116 278 290 10.1046/j.1365-2141.2002.03257.x 11841428 (Pubitemid 34156975)
48. YJ Cai QY Wei JG Fang L Yang ZL Liu JH Wyche Z Han 2004 The 3,4-dihydroxyl groups are important for trans-resveratrol analogs to exhibit enhanced antioxidant and apoptotic activities Anticancer Res 24 999 1002 1:CAS:528:DC%2BD2cXkvVenu78%3D 15161055
49. ZP Liu WX Li B Yu J Huang J Sun JS Huo CX Liu 2005 Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model J Med Food 8 14 19 1:CAS:528:DC%2BD2MXjsFCnsr0%3D 10.1089/jmf.2005.8.14 15857203 (Pubitemid 40617031)
50. NC Walsh TN Crotti SR Goldring EM Gravallese 2005 Rheumatic diseases: the effects of inflammation on bone Immunol Rev 208 228 251 1:CAS:528: DC%2BD28Xks1ehsA%3D%3D 10.1111/j.0105-2896.2005.00338.x 16313352
51. G Kuhnle JP Spencer G Chowrimootoo H Schroeter ES Debnam SK Srai C Rice-Evans U Hahn 2000 Resveratrol is absorbed in the small intestine as resveratrol glucuronide Biochem Biophys Res Commun 272 212 217 1:CAS:528:DC%2BD3cXkt1ansbo%3D 10.1006/bbrc.2000.2750 10872829 (Pubitemid 30444924)